



Organisation of Pharmaceutical Producers of India






हम हैं भारत

हम पहले भी थे, हम आज

THE POWER OF




त के लिए

भी हैं, हम कल भी रहेंगे।

PARTNERSHIPS

PARTNERSHIPS THAT SHAPED PROGRESS,
VOICES THAT SHAPED POLICY






For sixty years, OPPI has been more than an industry body — it has been a convener of dialogue, an advocate for balanced policy, and a builder of trust. Its impact has been shaped through collaboration: with government to frame regulation, with academia to expand knowledge, and with industry to raise standards of ethics and innovation.

This tradition of collective action shines through OPPI's Bharat Ke Liye campaign — a living affirmation that progress in healthcare flows from shared conviction, collaboration, and continuity.

Collaboration and dialogue have guided every step in shaping India's healthcare journey.

FOREWORD





Healthcare progress in India thrives on collaboration, dialogue, and shared vision. OPPI has championed these principles for sixty years, bringing together voices that enrich understanding: policymakers and scientists, industry leaders and academia, global perspectives and local priorities.

Through advocacy, OPPI has shaped policy and pricing frameworks — from patent legislation and drug price controls to contemporary reforms that ensure affordability and access. Its initiatives span knowledge dissemination through workshops, publications, and media columns, to awards recognizing scientific excellence, innovation, and leadership in patient care. Beyond the industry, OPPI has championed CSR programs, supported patient organizations, and promoted ethical standards, reinforcing integrity and confidence.

This book is a chronicle of those intersections. It traces the journey from OPPI's first policy memoranda to frameworks that guide access and innovation today; from awareness campaigns and ethical standards to partnerships that continue to place patients at the centre of healthcare. Each chapter captures not only events but the ongoing narrative of how dialogue, credibility, and collective purpose have shaped India's healthcare ecosystem.

Looking toward 2047, OPPI's journey demonstrates that lasting progress arises from discovery, advocacy, strong partnerships, thoughtful policy, and shared commitment.

Anil Matai
Director General, OPPI

Sixty years of advocacy and evidence-led action have strengthened healthcare across the nation.

1965–1975

FOUNDATIONS OF ADVOCACY
& COLLABORATION





Inception of OPPI brought together research-based pharmaceutical companies under a single voice of reputation and integrity. From the very beginning, industry leaders, scientists, and policymakers shared a table to debate ideas, advise on regulation, and build a framework for India's emerging pharmaceutical sector. Early contributions on the Patents Act and Pricing Policy via the Hathi Committee reflected a commitment to align science, industry, and public health priorities.

The careful cultivation of collaboration and dialogue set the tone for decades to come, embedding confidence and foresight at the heart of India's pharmaceutical growth.

Building credibility through early frameworks laid the foundation for a reliable pharmaceutical sector.

Building on the foundation of integrity and cooperation established at its inception, OPPI entered a phase of purposeful consolidation — strengthening its voice, communication, and reach. In 1972, OPPI became a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), aligning India's research-based pharmaceutical industry with global standards and perspectives. Around the same time, the establishment of its Delhi office deepened engagement with government departments, ensuring that policy dialogue remained continuous and informed.

Public awareness and professional communication also gained new platforms. Through the Health Education Campaign launched in 1973, OPPI sponsored a weekly 15-minute radio programme titled OPPI Medical Hour, bringing credible medical information directly to the public. The same year saw the launch of the OPPI Bulletin, a publication that connected members, shared insights, and documented evolving industry discourse.

Knowledge-sharing initiatives sowed the seeds for responsible, patient-centric progress.

By 1975, the release of the Member Directory consolidated these efforts — formalising communication networks and reinforcing a shared sense of purpose across the sector. Together, these initiatives created a framework for knowledge-sharing, set early principled standards, and fostered recognised advocacy — planting the seeds for enduring partnerships and patient-focused progress in the decades to follow.

The careful nurturing of dialogue, documentation, and shared learning reinforced OPPI's role as a convener of ideas and a custodian of principles, ensuring that every initiative contributed to a stronger, more coordinated pharmaceutical industry.





As the decade progressed, OPPI's efforts matured from foundation-building to national influence. Its growing participation in policy forums and consultations ensured that the evolving pharmaceutical framework aligned with India's public health priorities. Contributions to the 5th Five-Year Plan reflected a balance between industrial advancement and healthcare accessibility — positioning OPPI as a credible, solution-oriented partner to government and society alike.

Through structured advocacy, evidence-based recommendations, and consistent engagement with policymakers, OPPI helped shape an ecosystem grounded in transparency and shared responsibility. These efforts reinforced its standing as a custodian of principle-based standards, enabling the industry to navigate emerging regulatory landscapes with clarity, foresight, and confidence.

By the end of this formative decade, OPPI had established more than an institutional presence — it had created a culture of collaboration that would guide every milestone in India's pharmaceutical journey that followed.

Structured advocacy enabled the industry to navigate complex regulations with clarity.



1976–1985

POLICY ADVOCACY, ETHICAL
FRAMEWORKS, & EARLY INDUSTRY
COLLABORATION

DAGLI
COMMITTEE







With a foundation of trust and structured dialogue established, OPPI entered a more complex phase of industry engagement — one defined by policy advocacy, medical partnerships, and responsible communication. Rising challenges in drug pricing, import regulations, and industrial growth demanded a unified and informed voice.

The rationalisation of import duties on bulk drugs and intermediates strengthened domestic manufacturing and export potential, creating a more competitive sector. Workshops, roundtables, and conferences convened industry leaders, policymakers, and scientists to share insights and develop coordinated strategies that enabled the sector to respond effectively to new regulations while keeping patient welfare at the forefront.

During this period, OPPI's policy inputs and representations to key government committees — including the Dagli Committee on Drug Policy — helped shape approaches to pricing, technology transfer, and industrial participation. These structured interventions reinforced OPPI's credibility as an informed and balanced policy partner.

Structured engagement laid the groundwork for a resilient, patient-focused pharmaceutical ecosystem.




An in-depth survey of the basic issues involved in drug pricing and their implications for the growth of the Industry, originally published in "The Economic Times", Bombay.



This publication incorporates the Growth Plan for the Indian Pharmaceutical industry prepared by OPPI. Also includes the memoranda submitted by OPPI on the Hathi Committee Report covering "Development of the Drug Industry"; "Technology"; "Pricing", "Distributing of Drugs in Rural Areas" and "Brand Names".





OPPI's outreach expanded through publications such as The Pharmaceutical Industry – Drug Pricing Policy and Production and The Nation's Health and the Pharmaceutical Industry (1976–77), as well as through the acclaimed Health Education Campaign and OPPI Medical Hour radio programme, which built public awareness around medicines and healthcare.

In 1977–78, OPPI coordinated ₹17 lakh in relief for cyclone-affected communities in Andhra Pradesh and Tamil Nadu — ₹10 lakh in medicines and ₹7 lakh in cash — reflecting its growing social conscience. Its corporate communication programme was later cited as a model for other industry associations at the Sixth All-India Public Relations Conference (Cochin, 1978).

Advancing professional learning, OPPI partnered with the Indian Academy of Paediatrics and other specialist associations (1979–80) to support postgraduate medical education, reinforcing collaboration between industry and medicine.

By 1980, OPPI had recommended adoption of the IFPMA Code of Pharmaceutical Marketing Practices, and its membership in ASSOCHAM (1984) broadened its national policy platform.

By the end of the decade, these initiatives — from ethical frameworks and education to advocacy and relief — had embedded professionalism and integrity within India's pharmaceutical ecosystem.

Strategic advocacy and principled partnerships defined a decade of responsible growth.

1986–1995

IPR AWARENESS FOCUS ON
QUALITY & GOOD CORPORATE
GOVERNANCE PRACTICES





As India's pharmaceutical sector matured, OPPI's focus expanded from national advocacy to global engagement and quality assurance. The introduction of Good Manufacturing Practices (GMP) in the mid-1980s established safety and reliability as industry cornerstones, guiding manufacturing compliance and enhancing international credibility.

Preparation for the Drug Price Control Order (DPCO) 1987 saw OPPI lead structured dialogue between government and industry, presenting evidence-led recommendations that balanced affordability with sustainable growth. The formation of the Joint Council — uniting OPPI, IDMA, PAMDAL, and AIOCD — created a unified and credible voice for the sector on national policy issues, strengthening industry coordination and collaboration.

By 1989–90, India became a net foreign exchange earner, with pharmaceutical exports totaling ₹665 crore, surpassing imports. Workshops on quality, employee relations, and productivity engaged over 130 delegates, fostering shared learning and consistent industry standards. These initiatives underscored OPPI's growing role as a platform for dialogue, consensus, and continuous improvement.

Introducing GMP and early regulatory standards strengthened patient safety and industry recognition.

The early 1990's saw OPPI's advocacy expand into Intellectual Property Rights (IPR). Submissions to the Rajya Sabha Select Committee on the Patents Bill (1995) and TRIPS-focused workshops prepared Indian companies for global competition, balancing innovation incentives with public access to medicines.

Public engagement continued through studies such as the household medical expenditure survey of 1,500 households across eight cities, media campaigns, publications, and the video "Pharmaceuticals: A Lifeline Industry." Governance and business integrity committees were formed, establishing early industry standards for transparency and accountability.

OPPI's social commitment was reflected in extensive relief efforts — from drought and flood assistance to post-disaster medical support. The Emergency Medical Relief Supplies Fund ensured essential medicines reached those affected by natural calamities, including droughts, floods, and epidemics. Contributions included ₹1.5 lakh to the Maharashtra Chief Minister's Drought Relief Fund, medicines valued at ₹1 lakh for affected communities, and in 1993–94, medicines worth ₹50 lakh for earthquake relief in Latur, Maharashtra, in addition to cash donations.

These efforts demonstrated that healthcare progress extends beyond policy and innovation to compassion, action, and collective societal responsibility.

Empathy and accountability strengthened the connection between healthcare progress and community well-being.




Mr. H. Dhanrajgir President, addressing the 27th Annual General Meeting. From left are: Mr. R.D. Joshi, Secretary-General; Dr. Anil S. Mehta, Vice-President and Mr. Eduardo Faleiro, Hon'ble Minister of State for Chemicals & Fertilizers.



Dr. Prem Kumar Gupta, Drugs Controller, India, releasing the OPPI brochure "Research and Development in the Pharmaceutical Industry".



Medicines donated by OPPI Members for the relief work of the earthquake hit victims at Latur and other places in Maharashtra.



Mr. M.S. Gill, Secretary, Department of Chemicals & Petrochemicals, addressing the joint meeting of OPPI and IDMA regarding pricing and implementation of DPCO 1987 in Bombay.



Mr. R.K. Jaichandra Singh speaking at the Symposium on Quality Maintenance and Improvement jointly organised by OPPI, IDMA, PAMDAL and AIMO in Bombay.
A view of the large and distinguished audience.
Mr. H.K. Khan, Secretary, Department of Chemicals & Petrochemicals, addressing the Symposium.

1996–2005

ONE INDUSTRY, ONE VOICE AND
FOCUS ON INNOVATION & ACCESS





Entering a new era of reform and convergence, OPPI strengthened regulatory frameworks, expanded global engagement, and deepened policy alignment.

National seminars such as Healthcare Horizon and Focus on Pharmaceutical Industry (co-sponsored by IFPMA), along with workshops on clinical research, safety, and environment, equipped the sector to meet evolving global standards.

Policy advocacy intensified through submissions on the Patents (Second Amendment) Bill, DPCO amendments, and the DPEA. Partnerships with state chemists' associations and tax reforms in Maharashtra advanced affordability and industry growth.

A landmark collaboration with IDMA and IPA produced a Consensus Document on the New Drug Policy — the first unified industry representation in India's history. Joining the World Self-Medication Industry (WSMI), London, further connected Indian pharma to global self-care standards.

Unified advocacy and global alignment defined a decade of reform and responsibility.



Mr. Brian Toohey, Deputy Vice President, International Affairs, Pharmaceutical Research & Manufacturers of America (PhRMA), USA, addressing the Symposium on 'The New Patent Regime - Advantage India' held on July 22, 2005 in Mumbai.



Prof. Ramesh Panchagnula, NIPER, receiving the OPPI Scientist Award from Mr. Ranjit Shahani, President OPPI, at the 38th OPPI AGM



Bogie of Life Line Express, Dahanu Project where OPPI members donated medicines



Mr. Rajiv Shukla, Assistant Director, OPPI donating medicines for Mumbai Flood Victims to Shri Vilasrao Deshmukh, Hon'ble Chief Minister of Maharashtra.

Amid evolving healthcare reforms, OPPI focused on refining regulations, advancing research, and deepening public engagement. Submissions on the Patents (Second Amendment) Bill and DPCO revisions reflected balanced advocacy for innovation and access.

Public education expanded through films such as Pharmaceuticals: A Lifeline Industry and Matter of Life & Death, which simplified complex scientific themes for wider audiences. The OPPI Scientist Award (2002) celebrated excellence in pharmaceutical research, while CSR efforts supported hospitals, rural health, and disaster relief — translating industry responsibility into community impact.

Global participation through IFPMA and international forums reinforced OPPI's role as a convener of dialogue, standards, and responsible practice.


**Knowledge, recognition, and global collaboration
advanced innovation with purpose and compassion.**



2006–2015

SETTING INDUSTRY STANDARDS
& RECOGNISING TALENT





As India's healthcare landscape evolved, OPPI broadened its focus from advocacy to strengthening the nation's knowledge ecosystem. The Health Index of States offered a comprehensive view of regional performance, highlighting progress and gaps in access, infrastructure, and outcomes. Complementary studies on healthcare financing and investment priorities provided insights into systemic challenges and emerging opportunities.

By curating and communicating evidence from across the healthcare ecosystem, OPPI enabled policymakers, academia, and industry to make informed, data-led decisions that advanced patient care nationwide. These initiatives reinforced OPPI's position as a credible voice for evidence-based healthcare policy and reform.

Evidence-led insights illuminated pathways for equitable and progressive healthcare across India.

During this decade, OPPI focused on strengthening frameworks that upheld patient safety, ethical conduct, and responsible practice. Cold Chain Guidelines safeguarded temperature-sensitive medicines, Good Laboratory Practices (GLP) ensured research reliability, and Anti-Counterfeiting Guidelines reinforced market integrity. The DNA of Care and Patient Care handbooks encouraged companies to embed patient-centred values in everyday operations.

OPPI further expanded its knowledge platforms through publications such as OPPITUNITY, which showcased member initiatives, sector insights, and policy perspectives. Together, these initiatives reflected a vision of healthcare progress built on standards, accountability, and community participation.

**Healthcare progress
is sustained by strong
standards, trust, and
community participation.**



Mr. Ranjit Shahani, President, OPPI, releasing at 39th AGM "OPPI Guidelines on Good Laboratory Practices" developed by OPPI Technical Committee.



Winner of Woman Scientist Award: Dr (Mrs) Roshan Behram Colah, National Institute of Immunohaematology (NIIH), ICMR, Mumbai.



Handbooks




The first ever OPPI Lifetime Achievement award was presented to Nihchal H Israni, Chairman, Blue Cross Laboratories Ltd, recognising his contribution to the Indian pharmaceutical industry for over six decades.

Recognition and encouragement remained central to OPPI's ethos. The OPPI Young Scientist Award (2012) celebrated emerging innovators, while the Healthcare Access Awards (2013–14, 2015–16) honoured organisations and individuals advancing patient care. The Women Scientist Award (2014–15) highlighted pioneering contributions by female researchers, and the Lifetime Achievement Award (2014–15) recognised a legacy of enduring impact in healthcare.

The Dr. H. R. Nanji Memorial OPPI Marketing Excellence Awards, launched during this decade, celebrated creativity and responsible brand innovation — encouraging approaches that balanced business success with patient trust.

Together, these honours reflected OPPI's belief that recognition fuels responsibility. By celebrating achievement rooted in ethics and innovation, OPPI nurtured a culture of integrity, collaboration, and continual progress across the healthcare ecosystem.


Honouring innovation, integrity, and impact — inspiring excellence across healthcare.




The OPPI Healthcare Access Award was introduced for the first time in 2014. The award recognised the highest contribution by an individual or institution on Access to Healthcare with consideration for patient safety and adherence to quality. JAIPUR FOOT was declared the winner and the award was received by Padma Bhushan Devendra Raj Mehta, Founder and Chief patron of the Bhagwan Mahaveer Viklang Sahayata Samiti (BMVSS) for the exemplary work done for the rehabilitation of the physically disabled

2016–2025

FORWARD VISION &
BHARAT KE LIYE





Emerging at the crossroads of innovation, inclusion, and global partnership, OPPI entered a defining decade that reimagined healthcare in India. From policy to public engagement, it strengthened collaboration, knowledge-sharing, and principled advocacy — aligning India's pharmaceutical progress with the nation's broader aspirations for equitable health and economic resilience.

Landmark efforts such as Rule 101, the Rare Disease Policy, and the OTC Whitepaper translated insight into reform, while partnerships with McKinsey, PwC, and IFPMA deepened India's global dialogue on access and trust.

To advance public understanding, OPPI launched Know Your Pill — an initiative that demystified medicines and encouraged informed conversations between patients and healthcare professionals.

Publications like Healthcare in India: New Milestones... New Frontiers and the Health Meets Hope microsite captured member contributions to women's and child health, mental well-being, NCDs, and healthcare technology — reflecting an ecosystem powered by purpose, integrity, and shared progress.

Insight, integrity, and innovation converge to define the next horizon of Indian healthcare.

The pandemic became a crucible that tested resilience and redefined responsibility. As global supply chains fractured, OPPI and its member companies ensured uninterrupted access to essential medicines across India, strengthened hospital readiness with diagnostic systems such as CB-NAAT GeneXpert machines, and extended vital support through protective equipment and health infrastructure.

Through advocacy and guidance, OPPI helped shape a balanced national response — urging evidence-led policymaking on intellectual property, healthcare access, and digital innovation. The collective effort demonstrated how partnership and foresight could sustain both public health and industrial continuity in unprecedented times.

The COVID era transformed intent into insight — proving that when collaboration meets compassion, resilience becomes the foundation of progress.

From crisis emerged conviction — collaboration and compassion redefined resilience in healthcare.

 **OPPI** | **#HARGHARTIRANGA**
An embodiment of our commitment to nation-building.



#HarGharTiranga campaign



As recovery gave way to renewal, OPPI's purpose evolved from advocacy to nation-building. The Bharat Ke Liye campaign became the defining expression of this era — a collective commitment to align science, policy, and public good with India's vision of Viksit Bharat 2047. Through partnerships with government, academia, and global stakeholders, OPPI helped reimagine how India's pharmaceutical ecosystem could strengthen access, equity, and trust.

National engagement translated intent into impact through initiatives such as #HarGharTiranga, #Swachhata Pakhwada, and the OPPITUNITY publication, which showcased stories of youth skill development, science education, and rural livelihoods — connecting industry purpose with community progress.

Recognition reaffirmed responsibility. The OPPI-QCI Quality Award (2021) celebrated manufacturing excellence, while the Young Scientist, Women in STEM, and Healthcare Access Awards honoured ethical leadership and enduring contributions to patient welfare.

Together, these endeavours embodied OPPI's long-standing ethos — that progress in healthcare is sustained not by innovation alone, but by integrity, inclusion, and the power of partnerships.

Reimagining healthcare for a Viksit Bharat — where knowledge, compassion, and collaboration shape the nation's wellbeing.



OPPI Ratna Award 2023

Mr. Ranjit Shahani, Former President, OPPI. Award was accepted on behalf of Mr. Ranjit Shahani by his Son: **Mr. Siddharth Shahani**, Executive Director of ATLAS SkillTech University



BHARAT KE LIYE: A LEGACY OF COMMITMENT

Since 1965, OPPI has stood alongside India's healthcare ecosystem, bringing together industry, policymakers, scientists, and communities to advance public health. Its enduring contribution is defined by:



STRENGTHENING PARTNERSHIPS

Converging stakeholders to address national healthcare challenges.



ENABLING INNOVATION

Supporting collaborations that turn scientific discoveries into accessible healthcare solutions.



CHAMPIONING ETHICAL PRACTICES

Promoting integrity, standards, and patient-centric approaches across the sector.



WE WERE THERE

From its early years, OPPI helped unify the pharmaceutical industry's voice, contributing to

- **Policy Frameworks:** Supporting the development of regulations and healthcare policies
- **Access to Medicines:** Enabling the industry to expand availability of essential medicines
- **Public Health Initiatives:** Partnering in campaigns focused on disease prevention and awareness



WE ARE THERE

Today, OPPI continues to convene and enable

- **Collaborative Solutions:** Aligning government, industry, and academia to address contemporary healthcare needs
- **Knowledge Sharing:** Facilitating workshops, roundtables, and training on policy, regulatory, and clinical matters
- **Guiding Best Practices:** Advising on ethical, operational, and patient-focused standards across the industry





WE WILL BE THERE

Looking toward India@100, OPPI pledges to

- **Support Innovation through Partnerships:** Helping ensure research and development efforts translate into improved care
- **Enable Broader Access:** Working with stakeholders to enhance equitable healthcare delivery
- **Sustain Collaborative Progress:** Fostering multi-sector partnerships that strengthen healthcare systems and patient outcomes

We are Bharat Ke Liye
We were there,
We are there,
We will be there.



At the heart of OPPI's work is a manifesto of purposeful collaboration: Converge, Collaborate, Co-Create. By uniting policymakers, corporate stakeholders, research institutions, and local communities, OPPI facilitates knowledge exchange, aligns priorities, and co-develops solutions that strengthen patient care and expand access across India.

This approach honours the organisation's historic contributions while charting a clear path toward India@100 — a healthier, more resilient nation shaped by shared vision, ethical action, and evidence-based advocacy.



**From partnerships to progress,
from legacy to tomorrow — OPPI's
journey continues.**

INDIA@2047 VISION: A FUTURE-READY HEALTHCARE INDIA





Looking ahead to India@2047, OPPI envisions a healthcare ecosystem that is resilient, inclusive, and forward-looking. The coming decades will be defined by cutting-edge technologies, robust supply chains, and equitable health delivery for every citizen. By integrating insights from research, policy, and industrial expertise, OPPI and its member companies are shaping a strategic blueprint that ensures healthcare progress reaches all regions of the country.


This roadmap reflects decades of evidence-based advocacy, ethical standards, and coalition-driven action, ensuring India's healthcare journey remains citizen-focused while aligning with global best practices.



Empowering India with innovation, alliances, and equitable care for every citizen.

INDIA@2047 ROADMAP: STRUCTURES & MECHANISMS FOR ACTION





To translate vision into tangible results, OPPI has strengthened enabling mechanisms across India. Global Capability Centres (GCCs) and innovation hubs are harnessing scientific expertise, technological adoption, and collaborative networks to deliver solutions from labs to clinics.

Strategic coalitions with international partners amplify India's leadership in health science while maintaining citizen-focused priorities. Workshops, research collaborations, and policy engagement foster continuous knowledge exchange, ensuring every initiative aligns with sustainable healthcare growth.

By combining operational capacity, data-driven insights, and global benchmarking, OPPI and its members are embedding innovation and foresight into the healthcare ecosystem.

Scientific advancement and cross-sector collaboration convert vision into action.

INDIA@2047 ROADMAP







Innovation, partnerships, and strategic foresight will secure India's position as a global leader in patient-centric healthcare. By leveraging cutting-edge research, expanding the reach of Global Capability Centres (GCCs), and scaling innovation hubs across the country, OPPI and its member companies aim to deliver transformative healthcare solutions that reach every community.

Collaborations across public institutions, scientific communities, and healthcare enterprises transform ideas into measurable outcomes for citizens. Equitable access, advanced supply chains, and AI-driven insights will ensure that progress translates into meaningful outcomes for every patient. The roadmap combines technological potential, global collaboration, and patient-first principles to guarantee India's healthcare ecosystem is resilient, inclusive, and future-ready.

The power of partnerships drives India's healthcare forward — innovation, collaboration, and commitment shaping every patient's journey.

MESSAGE FROM THE PRESIDENT





OPPI's journey reflects a steadfast commitment to strengthening India's healthcare ecosystem through advocacy, partnership, and strategic guidance. Under the leadership of Bhushan Akshikar, the organisation continues to act as a convener and thought leader—uniting policymakers, industry leaders, and academic institutions to align on policies, digital health frameworks, and patient-centric initiatives.

“ By advancing dialogue on innovation, regulatory agility, and equitable access, OPPI helps shape an environment where healthcare solutions translate into measurable impact. Its engagement with Global Capability Centres (GCCs) and innovation hubs exemplifies this approach, reinforcing India's growing global influence while keeping national health priorities and patient welfare at the centre.

OPPI also champions sustainable access models, collaborative partnerships, and digital infrastructure that ensure rural and underserved communities are not left behind. These efforts reflect the organisation's Bharat Ke Liye ethos—converging expertise, co-creating solutions, and collaborating across sectors to strengthen the nation's health systems.

As India's healthcare landscape evolves rapidly, the nation stands poised to lead in drug discovery, digital health, and equitable access. Together, we will continue to shape the future of healthcare—with trust, scientific excellence, ethics, and innovation at its core.

Bhushan Akshikar

President, Organisation of Pharmaceutical Producers of India (OPPI)

VOICES THROUGH TIME — OPPI'S JOURNEY IN WORDS





● 1960s–1970s

“The purpose of this Association is to build bridges between industry, government, and science — for India’s progress in health.”

— OPPI Founding Charter, 1965

● 1980s

“Pharmaceutical innovation must go hand in hand with public trust and professional ethics.”

— OPPI Industry Statement, 1982 (Press Archive)

● 1990s

“Knowledge shared is health strengthened — through education, we enable safer and more informed healthcare.”

— OPPI ‘Know Your Pill’ Column, Express Pharma, 1999

● 2000s

“Scientific excellence is not a competition; it is a collective responsibility to patients.”

— OPPI Scientist Award Launch, 2002

● 2010s

“Healthcare progress must be measured by access, not just advancement.”

— OPPI Access and Equity Statement, 2015

● 2020s

“Reimagining healthcare for a Viksit Bharat — where innovation and partnership serve every patient.”

— OPPI Policy Vision, 2023

“We are Bharat Ke Liye — We were there, We are there,
We will be there.”

THE POWER OF PARTNERSHIPS:

A JOURNEY OF PROGRESS, 1965–2047

A LEGACY IN MOTION



Founded in purpose —
uniting research-driven
companies to strengthen
India's health systems.



Partnerships take root —
bringing science to communities
through awareness, vaccination,
and disease eradication
campaigns.



Reform and renewal —
championing ethics, intellectual
property protection, and
alignment with global best
practices.

2000s

India rises as the “Pharmacy of the World” — fostering access, trust, and international collaboration.



2010s

Innovation accelerates — digital health, research collaboration, and regulatory reform reshape the landscape.



2020s

Tested and transformed — pandemic partnerships define resilience; the 3C Manifesto reaffirms commitment.



2030-2047

The future unfolds — powered by AI, global capability centres, and positioning India as a global leader in equitable healthcare.



A LEGACY IN MOTION:
SIXTY YEARS OF
PARTNERSHIP AND
PROGRESS



For six decades, OPPI has been a steady engine of collaboration — enabling policy that balances access and innovation, raising quality standards, and turning evidence into action across the health ecosystem.

Concrete traces of that legacy:

- **Shaping policy:** sustained, technical inputs on patents, pricing and regulatory rules that informed national decisions.
- **Raising standards:** early advocacy for GMP, GLP, cold-chain and anti-counterfeiting frameworks that strengthened confidence across the supply chain.
- **Translating data into action:** Health Index of States and health-financing studies that guided targeted interventions.
- **Public clarity:** enduring education initiatives — columns, films and campaigns that demystified medicines and care.
- **Recognising excellence:** awards and fellowships that spotlight scientists, innovators and changemakers who serve patients.
- **Enabling reach:** CSR toolkits, patient-care handbooks and partner campaigns that supported last-mile delivery and community engagement.
- **Connecting to the world:** member-led GCCs and innovation hubs that link India's capabilities to global practice and opportunity.

These acts—practical, technical, cumulative—have moved systems, widened reach, and shaped better outcomes. This is OPPI's legacy in motion: quiet scaffolding that becomes public good.




THE EVOLUTION OF AN IDENTITY

AN EMBLEM IS NEVER JUST DESIGN — IT IS A DECLARATION OF PURPOSE.

Since its founding in 1965, the Organisation of Pharmaceutical Producers of India (OPPI) has stood for integrity, science, and partnership in service of public health. As India's healthcare ecosystem evolved through reform, innovation, and growing access, OPPI's identity evolved with it — each logo echoing the values, aspirations, and responsibilities of its time.

From the early insignia that reflected institutional credibility to the contemporary expression of agility and collaboration, every iteration of the OPPI mark captures a moment in this shared journey — one of renewal, relevance, and resolve.

What unfolds here is more than the evolution of a logo; it is the visual story of an organisation that has grown with India itself — steadfast in principle, adaptive in form, and enduring in its commitment to a healthier, progressive nation.



oppi



5 Years
HEALTHY INDIA
INNOVATIVE INDIA



Organisation of Pharmaceutical Producers of India


OPPI PRESIDENTS: LEADING THE PURPOSE

These are the Presidents who have shaped OPPI's legacy in motion — visionary leaders who steered the organisation through six decades of change, challenge, and progress. Each brought a distinctive voice to OPPI's mission: championing innovation, strengthening trust in science, and deepening collaboration across the healthcare ecosystem. Together, they embody a legacy of leadership that continues to propel OPPI forward.

The Presidents who led with foresight and conviction — decade after decade.



DR. H. R. NANJI
1966



MR. KEITH ROY
1967-1969



BRIG. B. S. BHAGAT
1970-1973



MR. S. V. PILLAI
1974-1975



MR. SISIR MITRA
1976-1978



MR. H. N. DUTT GUPTA
1979



DR. S. K.
BHATTACHARYA
1980-1981



MR. GEORGE DANIEL
1982-1984



MR. R. N. LANGRANA
1985



MR. C. M. HATTANGDI
1986-1987



DR. S. AGARWALA
1988-1990



MR. D. K. BOSE
1990-1992



MR. H. DHANRAJGIR
1992-1994



DR. ANIL MEHTA
1994-1996



MR. D. BHADURY
1996-1998



MR. HOMI
KHUSROKHAN
1998-2000



MR. P. GUPTA
2000-2001



MR. TAPAN RAY
Sept-Nov 2001 (Interim)



MR. RANJIT SHAHANI
2001-2007



MR. RANGA IYER
2007-2009



MR. RANJIT SHAHANI
2009-2013



DR. SHAILESH
AYYANGAR
2013-2017



MR. A. VAIDHEESH
2017-2020



MR. SHARAD TYAGI
2020-2021



MR. S. SRIDHAR
2021-2022



MR. SURESH
PATTATHIL
2022-2024



MR. BHUSHAN
AKSHIKAR
2024-Present

Connect with us on:



@OPPIIndia



Organisation of Pharmaceutical
Producers of India (OPPI)



OPPI India



communications@indiaoppi.com



www.indiaoppi.com

#BharatKeLiye



OPPI



Organisation of Pharmaceutical Producers of India

Registered Office: 1620, C Wing, One BKC, Bandra Kurla Complex,
Bandra East, Mumbai-400051, India.

Delhi Office: Avanta Business Centre, Cabin No. 3.08, 3rd Floor, Ambadeep Building,
K. G. Marg, Connaught Place, New Delhi - 110001, India.

Copyright©2025 OPPI